Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial

The purpose was to test whether physicians can validly and reproducibly diagnose diabetic sensorimotor polyneuropathy (DSPN). Twelve physicians assessed 24 patients with diabetes mellitus (DM) on consecutive days (576 examinations) with physical features and voice disguised. Results were compared to gold standard 75% group diagnosis (dx) and a nerve conduction score (Σ5 NC nds). Masking of patients was achieved. Reproducibility measured by the kappa coefficient and compared to Σ5 NC nd varied considerably among physicians: median and ranges: signs 0.8 (0.32–1.0); symptoms 0.79 (0.36–1.0), and diagnoses 0.47 (0.33–0.84), both low and high scores indicating poor performance. There was substantial agreement between 75% group dx and confirmed NC abnormality (abn). As compared to Σ5 NC, individual physicians' clinical dx was excessively variable and frequently inaccurate. Study physician dx from signs and symptoms were excessively variable, often overestimating DSPN. Specific approaches to improving clinical proficiency should be tested. Muscle Nerve 42:157–164, 2010

[1]  J. Pirart.  Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 , 1978, Diabetes Care.

[2]  P. Dyck,et al.  Chapter 36 – Nerve Tests Expressed as Percentiles, Normal Deviates, and Composite Scores , 2005 .

[3]  G. Gronseth,et al.  Distal symmetrical polyneuropathy: Definition for clinical research , 2005, Muscle & nerve.

[4]  M. B. Brown,et al.  Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy , 1999, Neurology.

[5]  F. Buchthal,et al.  Electrophysiological studies in diabetic neuropathy , 1970, Journal of neurology, neurosurgery, and psychiatry.

[6]  J. Kimura,et al.  F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy , 2000, Diabetologia.

[7]  L. Wilkins.  Quantitative sensory testing , 1993, Neurology.

[8]  G. Gronseth,et al.  Distal symmetric polyneuropathy: A definition for clinical research , 2005, Neurology.

[9]  D. W. Mulder,et al.  The neuropathies associated with diabetes mellitus: A clinical and electromyographic study of 103 unselected diabetic patients , 1961 .

[10]  Diabetic polyneuropathy in controlled clinical trials: Consensus report of the peripheral nerve society , 1995, Annals of neurology.

[11]  J. Leahy.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population: National Health and Nutrition Examination Survey 1999–2002 , 2007 .

[12]  P. Dyck.  Detection, characterization, and staging of polyneuropathy: Assessed in diabetics , 1988, Muscle & nerve.

[13]  J. McArthur,et al.  Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies , 1999, Neurology.

[14]  L. Bouter,et al.  Methods for assessing diabetic polyneuropathy: validity and reproducibility of the measurement of sensory symptom severity and nerve function tests. , 2000, Diabetes research and clinical practice.

[15]  Guidelines in electrodiagnostic medicine , 1992, Muscle & nerve.

[16]  W. J. Litchy,et al.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort , 1993, Neurology.

[17]  Dan Ziegler,et al.  Challenges in Design of Multicenter Trials , 2007, Diabetes Care.

[18]  W. Litchy,et al.  Individual attributes versus composite scores of nerve conduction abnormality: Sensitivity, reproducibility, and concordance with impairment , 2003, Muscle & nerve.

[19]  S. Evers,et al.  Reproducibility of different nerve conduction velocity measurements in healthy test subjects and patients suffering from diabetic polyneuropathy. , 1997, Electromyography and clinical neurophysiology.

[20]  James P. Boyle,et al.  Impact of Recent Increase in Incidence on Future Diabetes Burden , 2006, Diabetes Care.

[21]  L. Nora.  American Association of Electrodiagnostic Medicine Guidelines in Electrodiagnostic Medicine: Implanted cardioverters and defibrillators , 1996 .

[22]  Thomas P. Christensen.  The Clinical Laboratory Improvement Amendments of 1988. , 1989, Health Care Financing Review.

[23]  D. W. Mulder,et al.  The neuropathies associated with diabetes mellitus , 1961, Neurology.

[24]  L. Wilkins.  Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy , 2001, Neurology.